Pfizer’s stock has been in the red for the past three years, but a recent deal with the White House has given investors hope. The company will have a three-year grace period on tariffs and plans to invest $70 billion in research and manufacturing in the U.S. The stock is now in positive territory for 2025, with year-to-date gains around 3%. While Pfizer faces challenges like patent cliffs and declining COVID sales, CEO Albert Bourla plans to add new revenue through acquisitions and R&D. With a low valuation and growth opportunities, Pfizer may be a solid buy in the long run.

Investors should consider the risks before investing in Pfizer, as it faces uncertainties in vaccine sales and acquisitions. Despite recent gains, the company still has questions to answer regarding future growth. The stock’s beaten-down valuation, low P/E ratio, and margin of safety make it an attractive option for long-term investors. While short-term performance is uncertain, investing in Pfizer could lead to significant returns over time.

Read more at Nasdaq: Can Pfizer’s Stock Break This Disappointing Streak?